Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.


TSXV:QPT - Post by User

Comment by ARIMA11on Apr 16, 2021 11:41am
327 Views
Post# 33011089

RE:RE:Market is speaking

RE:RE:Market is speakingNever though getting 300M would be this easy. Ok maybe not! :)

Looks like the OQP AGM occured but OQP it still not trading.
https://www.morningstar.com/stocks/xkrx/078590/quote
https://oqp.co.kr/ir/public-disclosure/#

Thus far, it seems that the rejection of the opinion of the auditor has been made official.
OQP still has the pop up relating to the AGM and cease trade order on the site. Sigh.

 
Results of the regular shareholders' meeting
1. Approval and reporting of financial statements
28th (Unit: KRW million)
end. Individual (separate)-Total assets 470,375-Sales 37,468
-Total liabilities 357,890-Operating profit -10,765
-Capital 15,745-Net income -179,116
-Total equity 112,485 * Earnings per share (won) -2,448
I. Consolidated-Total assets 471,013-Sales 61,405
-Total liabilities 358,046-Operating profit -10,063
-Capital 15,745-Net income -179,510
-Total equity 112,967 * Earnings per share (won) -2,446
* Rejection of individual (separate) opinions from auditing auditors
Connection refusal
 
2. Dividend resolution and report
end. Cash·In-kind Dividend Dividend Type-
-Details of spot assets-
Dividend per share (KRW) Ending dividend for common stock-
Interim/Quarterly Dividend-
Kind Shares Ending Dividend-
Interim/Quarterly Dividend-
Total dividend (won)-
Dividend rate at market price (%) (including interim dividend) Common stock-
Kind Shares-
I. Stock dividend Stock dividend rate (%) Common stock-
Kind Shares-
Total Dividend Shares (Shares) Common Stock-
Kind Shares-
 
3. Executive status (as of the date of appointment)
end. Executive Appointment Status-
I. Number of outside directors after appointment (persons) Total number of directors 9
Total number of outside directors 3
Appointment ratio of outside directors (%) 33.33
All. Number of auditors after appointment (persons) Number of full-time auditors-
Number of part-time auditors 1
la. Number of audit committee members after appointment (persons) Audit committee members who are outside directors-
Number of audit committee members who are not outside directors-
 
4. Other resolutions Report agenda
1) Business report for the 28th term (2020 business year)
2) Audit report for the 28th term (2020 business year)
3) Report on the operation status of the internal accounting management system for the 28th term (2020 business year)
4) Report on appointment of external auditor
 
Negative agenda
1) Agenda #1: Approval of consolidated and separate financial statements for the 2020 fiscal year (including deficit treatment statement (draft))
=> Approved as original draft
 
2) Agenda 2: Partial amendment to the articles of incorporation
=> Approved as original draft
 
3) Agendum #3: Approval of the limit of compensation for directors in the 2021 fiscal year
=> Approved as original draft
 
4) Agendum #4: Approval of the limit of compensation for auditing in the 2021 fiscal year
=> Approved as original draft
 
5. Shareholders' Meeting Date 2021-04-14
6. Other references to investment decisions


<< Previous
Bullboard Posts
Next >>